AstraZeneca today announced its decision to withdraw the Marketing Authorisation Application (MAA) submitted to the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in June 2015 for cediranib in combination with platinum-based chemotherapy followed by maintenance monotherapy for the treatment of adult patients with platinum-sensitive relapsed ovarian cancer (including fallopian tube or primary peritoneal sub types).
Cediranib remains an important part of AstraZeneca’s ovarian cancer medicine pipeline and this decision does not affect the ongoing primary development programme testing cediranib as a combination treatment alongside the Company’s existing and potential medicines.
The decision to withdraw the MAA was based on outstanding questions raised by the European Medicines Agency (EMA) at this late stage of the review process. The MAA for cediranib was supported by data from ICON6, a Phase III trial led by investigators from University College London (UCL) and the Medical Research Council (MRC). AstraZeneca has not made additional regulatory submissions for cediranib in this indication in any other markets.
AstraZeneca is committed to enhancing treatment options for patients with ovarian cancer, including developing chemotherapy-free alternatives to help delay or avoid the use of platinum-based chemotherapies.
- ENDS -
NOTES TO EDITORS
ICON6 was a randomised, three-arm and two-stage double-blind placebo-controlled Phase III trial conducted in UK, Canada, Australia, New Zealand and Spain.It was designed to evaluate the safety and efficacy of platinum-based chemotherapy in combination with cediranib in women with platinum-sensitive relapsed ovarian cancer. The trial was developed by the International Collaboration for Ovarian Neoplasia (ICON) and Gynecologic Cancer InterGroup (GCIG) and led by the MRC Clinical Trials Unit at University College London.1
Cediranib is a novel, orally administered multi-Vascular Endothelial Growth Factor receptor (VEGFR) inhibitor which is currently being tested as a maintenance treatment in patients with platinum-sensitive relapsed (PSR) ovarian cancer. Cediranib inhibits tumour growth by stopping blood flow to the tumour site.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
|Neil Burrows||UK/Global||+44 203 749 5637|
|Vanessa Rhodes||UK/Global||+44 203 749 5736|
|Karen Birmingham||UK/Global||+44 203 749 5634|
|Rob Skelding||UK/Global||+44 203 749 5821|
|Jacob Lund||Sweden||+46 8 553 260 20|
|Michele Meixell||US||+1 302 885 2677|
|Thomas Kudsk Larsen||+44 203 749 5712|
|Craig Marks||Finance, Fixed Income, M&A||+44 7881 615 764|
|Nick Stone||Respiratory & Autoimmunity||+44 203 749 5716|
|Henry Wheeler||Oncology||+44 203 749 5797|
|Christer Gruvris||Infection & Neuroscience||+44 203 749 5711|
|Lindsey Trickett||Cardiovascular & Metabolic Diseases||+1 240 543 7970|
|Mitchell Chan||Oncology||+1 240 477 3771|
|Toll free||+1 866 381 7277|